An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia

This study has been terminated.
(Terminated due to suboptimal dosing schedule)
Information provided by:
Kyowa Hakko Kirin Pharma, Inc. Identifier:
First received: June 28, 2006
Last updated: June 22, 2010
Last verified: March 2008

Non-randomized, open, dose ranging and dose scheduling study of ascending doses of KW-2449 in subjects with AML, ALL, MDS and CML.

Condition Intervention Phase
Acute Myelogenous Leukemia
Acute Lymphoblastic Leukemia
Myelodysplastic Syndromes
Chronic Myelogenous Leukemia
Drug: KW-2449
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of KW-2449 in Acute Leukemias (AML), Myelodysplastic Syndromes (MDS), and Chronic Myelogenous Leukemia (CML)

Resource links provided by NLM:

Further study details as provided by Kyowa Hakko Kirin Pharma, Inc.:

Primary Outcome Measures:
  • To determine maximum tolerated dose of KW-2449 using prespecified dose limiting toxicity definitions based on CTCAE, version 3.0 and to assess tolerability based on adverse events [ Time Frame: For duration of dosing ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Pharmacokinetics [ Time Frame: For duration of dosing ] [ Designated as safety issue: No ]
  • Pharmacodynamics [ Time Frame: For duration of dosing ] [ Designated as safety issue: No ]
  • Clinical Response [ Time Frame: For duration of dosing ] [ Designated as safety issue: No ]

Enrollment: 37
Study Start Date: June 2006
Estimated Study Completion Date: April 2008
Estimated Primary Completion Date: April 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: KW-2449
Treatment with ascending doses of KW-2449
Drug: KW-2449
Sequential ascending oral doses of KW-2449 given for 14 or 28 days (modified by protocol amendment to only 14 days dosing).

Detailed Description:

This is a Phase I open-label dose escalation study of KW-2449 in subjects with acute leukemias, high risk MDS, and CML who are not candidates for approved therapy. Over an 18-month period, the investigative sites collectively will enroll up to a total of 96 subjects. Subjects will be enrolled sequentially into 1 of 7 dose groups to evaluate 2 dosing schedules (Arm A = 14 consecutive days of dosing followed by a 7-28 day rest period as determined by recovery from any acute hematologic and non-hematologic toxicities, or Arm B = 28 consecutive days of dosing followed by a 7-28 day rest period, as determined by recovery from any acute hematologic and non-hematologic toxicities). The safety of a dose level in Arm A (14-day dosing regimen) will be established prior to enrollment of subjects in the same dose level in Arm B (28-day dosing regimen).

In April 2007 the protocol was amended to discontinue Arm B (28 consecutive days of dosing). The protocol will continue as planned for Arm A (14 days of consecutive dosing).

Enrollment will proceed until a maximum tolerated dose (MTD) has been established for each study Arm. Once the MTD has been reached, 12 additional subjects, with 1 or more of the hematologic conditions included in this study, may be enrolled at the MTD as an expanded safety cohort.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Histologically confirmed diagnosis of:

    • AML (including APL refractory to all-trans retinoic acid and arsenic) that has relapsed or was not responsive to prior chemotherapy;
    • Relapsed/refractory ALL;
    • CML that has failed to respond or has lost a response to imatinib; and
    • Advanced MDS (INT-2 and High risk by IPSS) with failure or intolerance to approved therapy.
  2. ECOG Performance Status score of 0, 1, or 2;
  3. Male or female, at least 18 years of age;
  4. Signed written informed consent;
  5. Serum creatinine ≤ 2.0 mg/dL;
  6. Serum SGOT (AST) and SGPT (ALT) ≤ 5x ULN; serum bilirubin ≤ 2 mg/dL (serum bilirubin may be ≤ 3.0 mg/dL in any subject with Gilbert's Syndrome); and
  7. For females of childbearing potential, a negative serum pregnancy test. Subjects, of childbearing potential, must use an Investigator-approved method of birth control.

Exclusion Criteria:

  1. Candidates for approved therapies;
  2. Concomitant treatment with any investigational agent, chemotherapy, radiotherapy, or immunotherapy;
  3. Active CNS leukemia;
  4. Previous or concurrent malignancy except noninvasive non-melanomatous skin cancer, in situ carcinoma of the cervix, or other solid tumor treated curatively, and without evidence of recurrence for at least 2 years prior to study entry;
  5. Uncontrolled systemic infection (viral, bacterial, or fungal);
  6. Uncontrollable disseminated intravascular coagulation;
  7. Major surgery within the 28 days preceding the first dose KW-2449;
  8. Radiotherapy, or lack of recovery of any radiotherapy-related acute toxicity, within the 28 days preceding the first dose KW-2449;
  9. Treatment with systemic therapy for the underlying hematologic condition, or lack of recovery of toxicity from such treatment, within 28 days of the first dose of KW-2449, with the following exceptions: hydroxyurea for treatment of hyperleukocytosis (discontinued for at least 48 hours prior to the first dose of KW-2449); imatinib (discontinued for at least 48 hours prior to the first dose of KW-2449); and interferon (discontinued for at least 7 days prior to the first dose of KW-2449);
  10. Treatment with any other investigational agent, or lack of recovery of toxicity from such treatment, within the 28 days preceding the first dose of KW-2449;
  11. Positive serology for HIV;
  12. Clinically significant cardiac dysfunction (New York Heart Association Class 3 or 4) at the time of screening, or a history of myocardial infarction or heart failure within 3 months preceding the first dose of KW-2449;
  13. Any evidence of chronic Graft versus Host Disease;
  14. Active autoimmune disease requiring immunosuppressive therapy;
  15. Female subjects who are pregnant or breast feeding;
  16. Subjects of childbearing potential, unwilling to use an approved, effective means of contraception in accordance with the institution's standards;
  17. Known current drug or alcohol abuse;
  18. Other severe, acute, or chronic medical or psychiatric condition, or laboratory abnormality that may compromise the safety of the subject during the study, affect the subject's ability to complete the study, or interfere with interpretation of study results; or
  19. For any reason is judged by the Investigator to be inappropriate for study participation, including an inability to communicate or cooperate with the Investigator.
  20. Hematopoietic growth factors (i.e., such as erythropoietin or darbepoetin alpha, filgrastim [granulocyte colony-stimulating factor {G-CSF }], sargramostim [granulocyte-macrophage colony-stimulating factor {GM-CSF}], or other thrombopoietic agents) and corticosteroids within 14 days of study entry.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00346632

United States, Maryland
Johns Hopkins Hospital
Baltimore, Maryland, United States, 21287
United States, New Jersey
Contact Kyowa
Princeton, New Jersey, United States, 08540
United States, New York
Weill Cornell/New York Presbyterian Hospital
New York, New York, United States, 10021
United States, Texas
M.D. Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
Kyowa Hakko Kirin Pharma, Inc.
Study Director: Matt Fujimori, MD Kyowa Hakko Kirin Pharma, Inc.
  More Information

No publications provided by Kyowa Hakko Kirin Pharma, Inc.

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Allyson Pollack, Kyowa Pharmaceutical, Inc. Identifier: NCT00346632     History of Changes
Other Study ID Numbers: 2449-US-001
Study First Received: June 28, 2006
Last Updated: June 22, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by Kyowa Hakko Kirin Pharma, Inc.:
Kinase Inhibitor

Additional relevant MeSH terms:
Leukemia, Lymphoid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Myelodysplastic Syndromes
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Bone Marrow Diseases
Hematologic Diseases
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Myeloproliferative Disorders
Neoplasms by Histologic Type
Pathologic Processes
Precancerous Conditions processed this record on September 01, 2015